Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMK3C4L)

Drug Name

ELX-02 Drug Info

Synonyms

exaluren; ELX-02; Exaluren [INN]; TP732M43NA; 1375073-93-0; NB-124; HY-114231B; CS-0095334; ELX-02free; ELX-02 free; UNII-TP732M43NA; CHEMBL2220350; GTPL10944; EX-A7401; HY-114231; CS-0080240; (2R,3S,4R,5R,6S)-5-amino-6-[(1R,2R,3S,4R,6S)-4,6-diamino-2-[(2S,3R,4S,5R)-5-[(1S)-1-aminoethyl]-3,4-dihydroxyoxolan-2-yl]oxy-3-hydroxycyclohexyl]oxy-2-[(1R)-1-hydroxyethyl]oxane-3,4-diol; 4-O-(2-AMINO-2,7-DIDEOXY-D-GLYCERO-.ALPHA.-D-GLUCOHEPTOPYRANOSYL)-5-O-(5-AMINO-5,6-DIDEOXY-.ALPHA.-L-TALOFURANOSYL)-2-DEOXY-D-STREPTAMINE; D-STREPTAMINE, O-2-AMINO-2,7-DIDEOXY-D-GLYCERO-.ALPHA.-D-GLUCO-HEPTOPYRANOSYL-(1->4)-O-(5-AMINO-5,6-DIDEOXY-.ALPHA.-L-TALOFURANOSYL-(1->5))-2-DEOXY-; D-Streptamine, O-2-amino-2,7-dideoxy-D-glycero-alpha-D-gluco-heptopyranosyl-(1->4)-O-(5-amino-5,6-dideoxy-alpha-L-talofuranosyl-(1->5))-2-deoxy-; O-2-Amino-2,7-dideoxy-D-glycero-alpha-D-gluco-heptopyranosyl-(1->4)-O-(5-amino-5,6-dideoxy-alpha-L-talofuranosyl-(1->5))-2-deoxy-D-streptamine

Indication

Disease Entry	ICD 11	Status	REF
Cystic fibrosis	CA25	Phase 2	[1]

Cross-matching ID

PubChem CID: 71461382
TTD Drug ID: DMK3C4L

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Clinical Trial Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Ribosome (hRBS)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
TST-10088	DMT5AEF	Solid tumour/cancer	2A00-2F9Z	Phase 1	[3]
------------------------------------------------------------------------------------

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Ribosome (hRBS)	TTJ073B	NOUNIPROTAC	Modulator	[2]

------------------------------------------------------------------------------------

References

1	ClinicalTrials.gov (NCT04135495) A Phase 2 Open Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Dose Levels of Subcutaneously Administered ELX-02 in Patients With Cystic Fibrosis With at Least One G542X Allele. U.S.National Institutes of Health.
2	A Randomized, Double-Blind, Placebo-Controlled, Multiple Dose Escalation Study to Evaluate the Safety and Pharmacokinetics of ELX-02 in Healthy Subjects. Clin Pharmacol Drug Dev. 2021 Aug;10(8):859-869.
3	Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2009 Nov;31(9):597-633.